Iovance Biotherapeutics (IOVA)
(Delayed Data from NSDQ)
$8.73 USD
+0.29 (3.44%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $8.72 -0.01 (-0.11%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
Brokerage Reports
Iovance Biotherapeutics, Inc. [IOVA]
Reports for Purchase
Showing records 21 - 40 ( 187 total )
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Genomic Medicine Deep Dive-Redrawing Frontiers at the Coding Level
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Hold For IOV-LUN-202 With Zero Impact on Lifileucel PDUFA
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Three Near-Term PDUFAs Should Drive Significant Long-Time Coming Value
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q23 Results; Global Regulatory Efforts Take Center Stage; PDUFA Date 2/24/24; Price Target Lowered to $28
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
TILs Can''t Catch a Break; New PDUFA Date Set for February 24, 2024; Thesis Unchanged
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Upcoming WCLC ''23 Presentation Raises LN-145''s Profile in Advanced NSCLC
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q23 Results; Commercial Preparation in Full Gear; Lifileucel PDUFA November 25, 2023
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Iovance Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department